120 related articles for article (PubMed ID: 38568853)
1. Suppression of AGRN enhances CD8+ T cell recruitment and inhibits breast cancer progression.
Tao J; Shen L; Zhuang M; Zhai C; Zeng H; Mao Y; Liu X
FASEB J; 2024 Apr; 38(7):e23582. PubMed ID: 38568853
[TBL] [Abstract][Full Text] [Related]
2. Tumoral PD-1hiCD8+ T cells are partially exhausted and predict favorable outcome in triple-negative breast cancer.
Guo L; Cao C; Goswami S; Huang X; Ma L; Guo Y; Yang B; Li T; Chi Y; Zhang X; Wu J
Clin Sci (Lond); 2020 Apr; 134(7):711-726. PubMed ID: 32202617
[TBL] [Abstract][Full Text] [Related]
3. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
[TBL] [Abstract][Full Text] [Related]
4. A high CD8 to FOXP3 ratio in the tumor stroma and expression of PTEN in tumor cells are associated with improved survival in non-metastatic triple-negative breast carcinoma.
Tavares MC; Sampaio CD; Lima GE; Andrade VP; Gonçalves DG; Macedo MP; Cordeiro de Lima VC
BMC Cancer; 2021 Aug; 21(1):901. PubMed ID: 34362334
[TBL] [Abstract][Full Text] [Related]
5. PD-L1 silencing inhibits triple-negative breast cancer development and upregulates T-cell-induced pro-inflammatory cytokines.
Lotfinejad P; Kazemi T; Safaei S; Amini M; Roshani Asl E; Baghbani E; Sandoghchian Shotorbani S; Jadidi Niaragh F; Derakhshani A; Abdoli Shadbad M; Silvestris N; Baradaran B
Biomed Pharmacother; 2021 Jun; 138():111436. PubMed ID: 33667790
[TBL] [Abstract][Full Text] [Related]
6. Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression.
Yang F; Lin L; Li X; Wen R; Zhang X
Cell Biol Int; 2022 Nov; 46(11):1959-1969. PubMed ID: 35930601
[TBL] [Abstract][Full Text] [Related]
7. Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy.
Yazaki S; Shimoi T; Yoshida M; Sumiyoshi-Okuma H; Arakaki M; Saito A; Kita S; Yamamoto K; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Ohe Y; Fujiwara Y; Yonemori K
Breast Cancer Res Treat; 2023 Jan; 197(2):287-297. PubMed ID: 36385236
[TBL] [Abstract][Full Text] [Related]
8. Effector memory cytotoxic CD3
Sun X; Zhai J; Sun B; Parra ER; Jiang M; Ma W; Wang J; Kang AM; Kannan K; Pandurengan R; Zhang S; Solis LM; Haymaker CL; Raso MG; Mendoza Perez J; Sahin AA; Wistuba II; Yam C; Litton JK; Yang F
Mod Pathol; 2022 May; 35(5):601-608. PubMed ID: 34839351
[TBL] [Abstract][Full Text] [Related]
9. Histological spatial analysis on the induction of PD-L1
Suzuki K; Ohe R; Kabasawa T; Kitaoka T; Kawai M; Motoi F; Futakuchi M
Breast Cancer; 2023 Nov; 30(6):1094-1104. PubMed ID: 37792212
[TBL] [Abstract][Full Text] [Related]
10. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression in tumor lesions and soluble PD-L1 serum levels in patients with breast cancer: TNBC versus TPBC.
Yazdanpanah P; Alavianmehr A; Ghaderi A; Monabati A; Montazer M; Tahmasbi K; Farjadian S
Breast Dis; 2021; 40(1):43-50. PubMed ID: 33523034
[TBL] [Abstract][Full Text] [Related]
12. Treatment with eFT-508 increases chemosensitivity in breast cancer cells by modulating the tumor microenvironment.
Yang ZY; Jiang CW; Zhang WL; Sun G
J Transl Med; 2022 Jun; 20(1):276. PubMed ID: 35717238
[TBL] [Abstract][Full Text] [Related]
13. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
[TBL] [Abstract][Full Text] [Related]
14. Histological subtype is associated with PD-L1 expression and CD8+ T-cell infiltrates in triple-negative breast carcinoma.
Salisbury T; Abozina A; Zhang C; Mao E; Banyi N; Leo J; Ionescu D; Zhou C; Wang G
Ann Diagn Pathol; 2022 Apr; 57():151901. PubMed ID: 35091156
[TBL] [Abstract][Full Text] [Related]
15. Expression of PD-L1 in Early-Stage Invasive Breast Carcinoma and Its Relation to Tumor-Infiltrating Lymphocytes.
Amin NH; Abou-Bakr AA; Eissa S; Nassar HR; Eissa TS; Mohamed G
Asian Pac J Cancer Prev; 2022 Mar; 23(3):1091-1102. PubMed ID: 35345385
[TBL] [Abstract][Full Text] [Related]
16. Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes.
Ntostoglou K; Theodorou SDP; Proctor T; Nikas IP; Awounvo S; Sepsa A; Georgoulias V; Ryu HS; Pateras IS; Kittas C
Cancer Immunol Immunother; 2024 Feb; 73(3):46. PubMed ID: 38349444
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological and prognostic value of TIL and PD L1 in triple negative breast carcinomas.
Uğurluoğlu C; Yormaz S
Pathol Res Pract; 2023 Oct; 250():154828. PubMed ID: 37778126
[TBL] [Abstract][Full Text] [Related]
18. circ-0000512 inhibits PD-L1 ubiquitination through sponging miR-622/CMTM6 axis to promote triple-negative breast cancer and immune escape.
Dong LF; Chen FF; Fan YF; Zhang K; Chen HH
J Immunother Cancer; 2023 Jun; 11(6):. PubMed ID: 37349124
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells.
Tawfik O; Kimler BF; Karnik T; Shehata P
Hum Pathol; 2018 Oct; 80():170-178. PubMed ID: 29936058
[TBL] [Abstract][Full Text] [Related]
20. Exploratory analysis of immune checkpoint receptor expression by circulating T cells and tumor specimens in patients receiving neo-adjuvant chemotherapy for operable breast cancer.
Wesolowski R; Stiff A; Quiroga D; McQuinn C; Li Z; Nitta H; Savardekar H; Benner B; Ramaswamy B; Lustberg M; Layman RM; Macrae E; Kassem M; Williams N; Sardesai S; VanDeusen J; Stover D; Cherian M; Mace TA; Yu L; Duggan M; Carson WE
BMC Cancer; 2020 May; 20(1):445. PubMed ID: 32429929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
